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EnzymeThe identiﬁcation of disturbances in the cellular structure, electrophysiology and calcium handling of atrial
cardiomyocytes is crucial to the understanding of common pathologies such as atrial ﬁbrillation. Human right
atrial specimens can be obtained during routine cardiac surgery andmay be used for isolation of atrial myocytes.
These samples provide the unique opportunity to directly investigate the effects of human disease on atrial
myocytes. However, atrial myocytes vary greatly between patients, there is little if any access to truly healthy
controls and the challenges associatedwith assessing the in vivo effects of drugs or devices inman are considerable.
These issues highlight the need for animal models. Large mammalian models are particularly suitable for this
purpose as their cardiac structure and electrophysiology are comparable with humans. Here, we review techniques
for obtaining atrial cardiomyocytes.We start with background information on solution composition. Agents shown
to increase viable cell yieldwill then be explored followed by a discussion of the use of tissue-dissociating enzymes.
Protocols are detailed for the perfusionmethod of cell isolation in largemammals and the chunk digest methods of
cell isolation in humans.
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Physiological salines used in cardiac research (in mmol/L) [118].
Ringer [17] Locke [18] Tyrode [19] Krebs and Henseleit [20]
NaCl 116 154 137 117
KCl 1.2 5.6 2.7 4.7
CaCl2 1 2.1 1.8 2.5
MgSO4 1.2
MgCl2 1.1
NaHCO3 2.7 2.4 11.9 24.8
NaH2PO4 0.4
KH2PO4 1.2
Glucose 5.6 5.6 11.1
pH 7.4
CO2 5%1. Introduction
Disease of the cardiac atria is a large and growing global problem.
Atrial ﬁbrillation (AF) is the most prevalent arrhythmia in the devel-
oped world, affecting 33 million patients globally [1]. Current pharma-
cological options have imperfect efﬁcacy and substantial adverse side-
effects, including drug-induced proarrythmia and both cardiac and
non-cardiac toxicity [2–4]. The limited effectiveness of current pharma-
cology is likely to result from an incomplete understanding of the path-
ophysiology of this complex heart rhythm disorder. Understanding the
processes underlying AF requires investigation at several scales. Whilst
studies at a whole-animal, whole-organ and tissue level have provided
many insights into the origins of arrhythmia initiation and perpetuation
[5], elucidating the pathological changes in ion currents, Ca2+ handling,
and cellular microstructure requires isolated cardiomyocytes.
Much of our understanding of myocyte physiology has been obtain-
ed from rodent models [6–8], from which cell isolation has recently
been reviewed [9]. Human electrophysiology, however, differs in sever-
al fundamental regards from these species. Examples of this include a
ﬁve to ten-fold difference in resting heart rate [10], a markedly different
complement of ion channels [11] and the presence of some transverse
tubules in the atria of large mammals [12–14]. To this end, a potentially
more fertile ground for understanding human disease is investigating
cardiomyocytes obtained from humans or other large mammals.
This review aims to ﬁnd the common thread that runs through the
atrial isolation protocols that have been evolving for more than
30 years [15]. There is a paucity of papers directly comparing isolation
techniques [16] and therefore themethod sections from individual cita-
tions have been compared. A representative paper describing the proto-
col used by each research group can be found in the supplemental
materials.
The theory underlying atrialmyocyte isolationwill be reviewed, and
factors shown to inﬂuence cell yield and quality discussed. Some
reagents, whilst improving cell quality for a speciﬁc experiment, may
be detrimental to the requirements of a different investigation. Knowl-
edge of these principles will therefore allow the isolation protocol to be
tailored to the experiment in hand. This will be followed by examples of
protocols that have proved successful for obtaining myocytes from
humans and large mammals.
1.1. Search strategy
Examples of protocols were found by searching PubMed using the
terms “atrial myocytes” OR “atrial cells” OR “heart cells” from 1st Octo-
ber 1980 to 1st April 2015, written in English and excluding reviews.
Human studies were found by ﬁltering for “human”, whilst reports on
large mammalian species were found using the additional search
terms of “dog” OR “canine”, “sheep” OR “ovine”, “goat”, “pig” OR
“porcine” OR “swine” NOT “guinea pig”. References from key review
articles on atrial electrophysiology were also identiﬁed.
2. Saline solutions
The basic composition of all solutions used for cell isolation is usually
based on established physiological saline solutions. Historically, thesewere formulated by empirically adjusting ion concentrations until the
solutions were considered acceptable in terms of the behaviour and
survival of a speciﬁc tissue. Physiological salines which are commonly
used in experimental cardiac research are shown in Table 1.
In his famous publications from the early 1880s Sydney Ringer
described for the ﬁrst time the importance of proper extracellular ion
concentrations for thephysiological function of the heart [17], establish-
ing the importance of Na+, K+ and Ca2+ ions to maintain continuous
beating of an isolated frog heart. To prevent acidiﬁcation by metabolic
products, he included bicarbonate buffers to maintain the cardiac con-
tractions for longer periods. Later Locke [18] adapted Ringer's solution
to the mammalian heart, by increasing salt concentrations. Locke also
added 5.6 mmol/L glucose (0.1%)which substantially increased the sur-
vival time of the heart. Maurice Tyrode's widely used saline was origi-
nally developed to maintain contractions of isolated rabbit intestine
[19]. He added magnesium and improved buffering by adding
phosphate and increasing the concentration of bicarbonate.
Krebs and Henseleit performed experiments on liver sections [20].
They further adapted available physiological salines to resemble the
composition of mammalian plasma by including sulphate and increas-
ing the concentration of phosphate. They used higher concentrations
of bicarbonate and gassed their solution with carbogen (5% CO2,
95% O2) to achieve a pH of 7.4.
Many of the physiological salines used today are based on the
formulations described above. Usually more modern buffers, such as
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) or MOPS
(3-(N-morpholino) propanesulfonic acid) are added to help maintain
constant pH as their pKa values are close to normal blood pH. Further-
more metabolic substrates such as pyruvic acid, β-hydroxybutyrate,
glutamic acid, oxalic acid or succinate may be included in addition to
glucose. Bovine serum albumin (BSA, 0.1–7%) is commonly used in
experimental solutions to maintain colloid osmotic pressure, thereby
preventing oedema [21], and to reduce nonspeciﬁc binding of proteins
and toxins used for experimental research [22]. At higher concentra-
tions, BSA is also used to inhibit enzyme activity [23].
These physiological salines have been optimised for different stages
of the isolation process. The following section will describe the typical
solutions used for (i) cardioplegia and tissue transport, (ii) Ca2+-free
solutions used for tissue dissociation, and (iii) storage solutions that
are used once single myocytes have been obtained.
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Cardioplegic solutions are used during cardiac surgery to halt
myocardial contraction, referred to as diastolic arrest. This decreases
myocardial metabolic demands and slows the degenerative processes
that follow ischaemia. The composition of commonly used transport
solutions is comparable to cardioplegic solutions used for cardiopulmo-
nary bypass surgery. The usage of cardioplegic solutions is almost
ubiquitous in human work (Supplemental Table 4 and [24–33]), and
these solutions are also used by some groups for isolation of atrial
myocytes from large mammals [34–36].
Cardioplegic solutions are subdivided into extracellular vs. intracel-
lular solutions based on their relative concentrations of Na+, Ca2+
and K+. Extracellular type solutions contain physiological Na+ and
Ca2+, achieving diastolic arrest through hyperkalemia resulting in
depolarisation of the cell membrane. St. Thomas solution no II, the
most widely used cardioplegic solution in cardiac surgery, was success-
fully applied as transport medium for atrial specimens [37]. Its formula-
tion, which is based on Ringer's solution, to which potassium chloride
and magnesium chloride were added, originates from the St. Thomas
Hospital in London [38].
Intracellular type cardioplegic solutions have a lowNa+ and/or Ca2+
content, similar to thatwhich is found in the cell cytoplasm. Diastolic ar-
rest is caused by offsetting of the transsarcolemmalNa+ gradient, there-
by reducing the driving-force of the fast Na+ current responsible for the
upstroke of the cardiac action potential. Reduced Ca2+ concentrations
limit contraction and reduce ischaemia-induced Ca2+ entry.
Bretschneider solution, a commonly used commercially available intra-
cellular cardioplegic solution, contains histidine, tryptophan and
ketoglutarate andwas usedbyHoppe andBeukelmann as transportme-
dium for atrial tissue samples [39]. The low-Ca2+ solutions used during
enzymatic digestions (see below) can also be seen as part of the family
of intracellular cardioplegic solutions, and can therefore also be used as
transport solution.
In addition to chemically-induced diastolic arrest, hypothermia re-
duces myocardial oxygen demands and slows cellular degeneration
during transport. In addition, low temperatures may also reduce the
detrimental effects of the Ca2+paradox (see below). Whilst transport
at 4 °C is used by some groups [34,36], we have not in our experience
found a clear advantage to cooling or oxygenation with transport
times between 30 and 45 min with respect to both number and quality
of isolated atrial cardiomyocytes. In general transport to the lab should
be as quick as possible. If longer transportation time cannot be avoided,
transport at 4 °C in oxygenated solution may be advantageous.
4. Ca2+-free solutions and the Ca2+ paradox
Once material has been transported to the laboratory, a separate so-
lution is often used to dissociate the tissue. One common feature of all
protocols used for isolation of single myocytes is a period of perfusion
with a nominally Ca2+-free solution (low Ca2+ solution). Even the ear-
liest reports of successful isolation of myocytes from adult animals take
advantage of Ca2+-free buffers. It is assumed that this Ca2+-free period
is necessary to allow cell separation at the intercalated discs [40]. This
may occur via disruption of the Ca2+-dependent cadherins thatmediate
adherens and desmosomal junctions betweenmyocytes [41]. Ca2+-free
perfusion also causes separation of the layers at the cell surface
(external lamina from myocyte surface coat [42]), which may lead to
the surface ‘blebs’ occasionally seen on isolated cells.
However, perfusion of either cardiac myocytes or the intact heart
with Ca2+-free solution has a major disadvantage ﬁrst described by
Zimmerman and Hulsmann [43]. They observed that after exposure of
the heart to Ca2+-free solution, reintroduction of Ca2+ into the perfu-
sion ﬂuid causes tissue disruption with marked contracture and release
of intracellular enzymes. This phenomenon is known as the “calcium
paradox” and results in irreversible hypercontraction of over 50% ofisolated myocytes [44]. The Ca2+ paradox is assumed to be caused by
an excessive increase of intracellular Ca2+ resulting in massive release
of enzymes, exhaustion of tissue high-energy phosphates, and ultra-
structural damage including contracture of myoﬁlaments and mito-
chondrial swelling (For review see Piper 2010 [45]).
There are two main hypotheses regarding the mechanisms
underlying the Ca2+ paradox. (1) The partial cellular uncoupling during
Ca2+-free perfusion means that myocyte contractile force is focused
solely on the residual adherent areas during Ca2+ reintroduction [46].
This leads to mechanical damage through sarcolemmal perforation,
massive Ca2+ inﬂux, and sarcolemmal disruption. (2) The sarcolemma
becomes abnormally permeable to electrolytes and/or water during
Ca2+-free perfusion, potentially due to Na+ loading via Na+/Ca2+ ex-
changer. Upon Ca2+ reintroduction, uncontrolled Ca2+ inﬂux ensues,
either through reverse Na+/Ca2+ exchanger [47] or via transient
receptor potential cation (TRPC) channels [44].
Protecting myocytes from the deleterious effects of the Ca2+ para-
dox has been suggested to increase the quality and quantity of isolated
cells. The following section details interventions that have been
suggested to increase Ca2+-tolerant myocyte yield.4.1. Duration of Ca2+-free perfusion
Contraction is curtailed in the absence of Ca2+, and upon reperfusion
with solutions containing Ca2+, a regeneration of contractile force is
seen as a marker of myocyte health. In rat hearts, exposure to greater
than ﬁve minutes of Ca2+-free medium completely abolished force re-
generation while shorter exposures did not [48]. This suggests that lim-
iting exposure to Ca2+-free mediummay have a beneﬁcial effect on the
isolation of cardiac myocytes. Therefore Lalevee et al. [49] and Varro
et al. [50] performed the enzymatic digestion in the presence of Ca2+
(10 μmol/L and 300 μmol/L, respectively) and introduced a washing
step with nominally Ca2+-free solution in between. Varro et al. clearly
state that too brief exposure to the nominally Ca2+-free solution
probably failed to cause the intercellular junctions to disconnect,
while too long an exposure yielded myocytes that were intolerant of
Ca2+.4.2. Temperature and pH
The Ca2+ paradox is strongly dependent on temperature. Perfusion
with Ca2+ free solution at 4 °C, followed by the restoration of Ca2+, per-
mitted recovery of cardiac function upon warming and protection of
cellular organelles while a constant temperature of 37 °C throughout
the procedure led to irreversible myocytolysis [51]. It is assumed that
the reduced temperature prevents separation of the fuzz-like glycopro-
teins that cover the cell membrane (the glycocalyx) and limits cytosolic
Ca2+ uptake upon Ca2+ restoration [52]. In order to take advantage of
the protective effect of reduced temperature, the initial washing steps,
which are usually performed in Ca2+-free solution, may be performed
at room temperature [15,53]. However, the narrow optimum tempera-
ture of digestive enzymes around 37 °C limits the value of this approach
for the cell isolation procedure. Isolation of rat ventricular myocytes at
20 °C has been reported [54] and amethod has been described for isolat-
ing human atrial myocytes at 30 °C [55]. Nevertheless, the vast majority
of laboratories performenzymatic digestion at 35–37 °C (Supplementary
Tables 2 and 4; large mammals and humans respectively).
It has been suggested that a reduction of the pH to 6.8 increases the
time period of Ca2+-free perfusion above which reintroduction of Ca2+
evokes the Ca2+ paradox [56]. It is assumed that the high extracellular
H+ concentration favours the extrusion of intracellular Na+ by the
Na+/H+-exchanger and thereby reduces the Na+ load. In accordance,
several groups use the beneﬁcial effects of a lower pH during perfusion
of tissue with low-Ca2+ solution [55,57].
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Since Na+ overloadmay play a crucial role in the pathophysiology of
the Ca2+ paradox, it has been suggested that decreasing Na+ in the
Ca2+-free solution could also prevent the Ca2+ paradox [48]. Following
this hypothesis Gintant [58] and Hatem et al. [59] used Ca2+-free solu-
tions without Na+ or with a low Na+ concentration, respectively.
As discussed above, one factor likely to contribute to the Ca2+ para-
dox is the increased sarcolemmal permeability to electrolytes and/or
water, leading to excessive osmotic swelling upon the return of Ca2+.
Reducing the Na+ concentration in the Ca2+-free solution may further
exacerbate the osmotic swelling. In contrast, it has been shown that in-
creasing the extracellular osmotic pressure can attenuate cell damage
during Ca2+ repletion [60]. Commonly used for this purpose are colloids
such as BSA [61], sugar alcohols such as mannitol [36] and sugars such
as sucrose, rafﬁnose and saccharose [37]. Glucose is often used, but is
not generally ideal since it can be taken up by cells and metabolised.4.4. Taurine and creatine
Isolation ofmyocytes leads to the loss of speciﬁc cellular compounds,
and there may be beneﬁt in supplementing these in the perfusing solu-
tions. Taurine is a highly prevalent amino-sulfonic acid with a diverse
range of physiological effects on the heart, retina, skeletal muscle, and
central nervous system [62]. Kramer et al. [63] showed that intracellular
taurine concentrations decrease during development of the Ca2+ para-
dox. When 10 mmol/L taurine was applied to isolated rat hearts during
the Ca2+-free period, a dramatic increase in recovery of mechanical
function and a decrease in loss of nucleotides and creatine phosphokinase
was seen. It is assumed that high intracellular levels of taurine (either due
to taurine uptake or reduced taurine loss in taurine-containing solutions)
activate a sarcolemmal taurine/Na+-symporter which limits the rise
of intracellular Na+ during the Ca2+-free period [64]. Inclusion of
taurine in the Ca2+-free solution is therefore presumed to have
beneﬁcial effects on the Ca2+ tolerance of isolated cardiac myocytes
[24–33,65,66].
Similarly, a loss of cellular creatine has been reported during isola-
tion of mouse ventricular myocytes [67]. When creatine was added to
digestion buffers, cellular viability and performance were enhanced.
Supplemental creatine has also been used empirically during the isola-
tion of canine atrial myocytes [58].4.5. Uncoupling agents
One of themain determinants of the Ca2+ paradox is extensive Ca2+
inﬂux into the cytosol, which is paralleled by amassive cellular contrac-
tion. Contraction-induced sarcolemmal disruption may be responsible
for loss of intracellular components and thereby play a major role in
the detrimental effects of the Ca2+ paradox [46]. 2,3-butanedione
monoxime (BDM) uncouples excitation–contraction by inhibiting
ATPase activity of myosin II [68]. Adding BDM during the last 2 min of
Ca2+-free perfusion reduces the loss of intracellular components upon
Ca2+ reintroduction, suggesting a cardioprotective effect of this drug
[69]. However, BDM has various side effects, such as nonspeciﬁc
phosphatase activity, which leads to alterations in the action potential,
altered Ca2+-handling and depletion of cellular ATP stores [70,71].
This may hamper its general usage during isolation of atrial myocytes.
Blebbistatin, a myosin II inhibitor, is widely used for excitation–con-
traction uncoupling in optical mapping. No signiﬁcant effects of
blebbistatin on the electrocardiogram, electrical conduction, or action
potential waveform have been reported in the mouse [72] and rat
[73]. Other groups, however, have reported blebbistatin-induced action
potential prolongation in Langendorff-perfused rabbit ventricle [74].
Blebbistatin has been used as an alternative to BDM [75].5. Enzymatic digestion
Isolation of single cells requires breakdown of the extracellular ma-
trix (ECM) which is the structural scaffold supporting myocytes. Apart
from the mechanical (trituration) and chemical (Ca2+ omission, use of
chelating agents) methods of ECM breakdown, the use of tissue-
dissociating enzymes represents the most important determinant of
cell dissociation.
The ECM comprises a ﬁbrous component, the main constituents of
which are types I and III collagen [76] but also includes elastin. This is
complemented by an amorphous “ground substance” containing hydro-
philic polysaccharides (e.g. glycosaminoglycans) and multi-adhesive
glycoproteins such as laminin or ﬁbronectin, which provide strength
to the tissue by binding to integrins on the surface of myocytes [77].
The ability of collagenases to digest heart tissue iswell known [78]. It
is notable that diseases such as heart failure or atrial ﬁbrillation result in
remodelling of the ECMwhere collagen abundance, type, and structure
can be altered (for review see [2,79,80]) and thus cell isolation tech-
niques require adaptation to given disease states.
Many investigators use a combination of collagenases and a general
protease to isolate cells frommammalian atria. The idea that both were
essential to produce viable cells was raised by Kono et al. [81], who in
1969 successfully isolated rat ventricularmyocytes using a combination
of collagenase, trypsin and chymotrypsin. Isolation was unsuccessful
when either amixture of puriﬁed collagenases alone or when amixture
of trypsin and chymotrypsin were used. These ﬁndings suggested that
cardiac extracellular matrix contains two components: the ﬁrst is di-
gestible with puriﬁed collagenases, and the second digestible with a
general protease. It has therefore been thought that collagen's triple he-
lical structure is resistant to proteolytic damage. The unique ability of
collagenases to crack the collagen structure has been thought necessary
to initiate digestion [82], and only after this initial cleavage are the col-
lagen fragments accessible to hydrolytic digestion by other less speciﬁc
proteases. Other ECM macromolecules (i.e., glycoproteins, proteogly-
cans) are, at this time, degraded by neutral protease activity [83].
However, protocols using a primary digestion with protease, only later
employing collagenase have been described [84], as have protocols
using collagenase alone [85,86].
5.1. Collagenase preparations from Clostridium histolyticum
Commercially available “collagenases” are usually puriﬁed from su-
pernatants of Clostridium histolyticum cultures. These “collagenases”
are crude preparation containing more than 30 different enzymes in-
cluding casein-digesting proteases, cellular debris, pigments and endo-
toxins [87]. Seven forms of collagenase have been puriﬁed from
Clostridium, which fall into two classes [88]. Studies on substrate spec-
iﬁcity revealed that class I collagenases encoded by the colG gene prefer
natural substrates such as intact collagen whereas class II collagenases
encoded by colH seem to act preferentially on short synthetic substrates
[89]. Highly puriﬁed collagenases have been shown to be of limited use
for the isolation of cardiac myocytes when applied alone [81], instead
requiring additional proteases to achieve respectable cell yields.
In contrast to vertebrate collagenases, clostridial collagenases can
make multiple cleavages within the triple helical regions and can also
degrade denatured collagen [88]. Conversely, vertebrate collagenases
initiate hydrolysis of collagen by making a single cleavage through all
three chains after which other proteases then carry out the hydrolysis
of the denatured collagen fragments (gelatinase activity). In addition,
clostridial collagenases can digest almost all types of collagen, making
them the enzymes of choice for digestion of extracellular tissue and
cell dissociation.
Collagenase preparations exhibit a high batch-dependent variability
in their precise enzyme composition and suppliers group each batch
into distinct collagenase “types”. These classiﬁcations are based onmea-
surements of collagenase activity and behaviour of other proteolytic
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general agreement concerning speciﬁcations of collagenase “types”,
these types are hardly comparable between different suppliers. Batch-
to-batch variability in enzyme activities (see above) requires newly ac-
quired batches to be tested at different concentrations. This is perhaps
the most critical determinant of successful cardiomyocyte isolation.
Samples can be obtained from manufacturers at no cost.
An in-depth description of the various assays to determine these
enzymes' activities is beyond the scope of this review and we refer the
interested reader to recent publications covering this issue [83].
A relatively new approach of suppliers to resolve the batch-
dependent variability is the introduction of enzyme preparations
consisting of blends of highly puriﬁed collagenase activities. This type
of enzyme has been successfully used to isolate atrial cells from mouse
[90], rabbit [91] and rat [92]. However, Kaestner et al. [23], isolating
human atrial myocytes, directly compared a puriﬁed collagenase
blend (Blendzyme 4, Roche) with the more commonly used crude
collagenase mix. They reported that Blendzyme produced poor cell
yields, an outcome that we have also found in our own experience.
5.2. Proteases
Proteases have been found to aid myocyte isolation in the hands of
most [81] if not all investigators [86,93]. Trypsin is a serine protease
which cleaves proteins and peptides within the amino acid chain
(endoprotease) on the C-terminal side of lysine and arginine amino
acid residues. Its pH optimum lies between 7.5 and 8.5 and its temper-
ature optimum is at 37 °C [94], making this enzyme suitable for cell iso-
lation. Trypsin was used in the earliest reports of cardiomyocyte
isolation [95], and is used by several groups for isolation of human atrial
myocytes [96], although to the best of our knowledge has not been used
to isolate atrial cells from other large mammalian species.
Other proteases are commonly used for isolation of both human and
large mammalian atrial myocytes, such as subtilisin Carlsberg (Protease
XXIV, former Protease VII, Sigma-Aldrich) obtained from Bacillus
licheniformis [97]. Similar to trypsin, subtilisin Carlsberg is a serine
endoprotease with pH-optimum of 7.5. It retains its activity at higher
temperatures and is widely used in modern laundry detergents. Other
groups use “pronase E” (Protease XIV, Sigma-Aldrich) derived from
Streptomyces griseus [39]. Pronase E is non-speciﬁc containing at least
10 proteolytic enzymes [98]. The optimum pH for pronase E is between
seven and eight and it has a wide range of working temperature. While
inclusion of such proteases aids cell isolation, other proteins such as ion
channels may also be degraded, speciﬁcally those carrying the K+
current IKr [99].
Cardiac ECM also contains elastin ﬁbres and elastase is the only neu-
tral protease which is able to digest this protein. Some investigators
have therefore found it useful to include elastase in the isolation of
human atrial myocytes [49]. Elastase has not been used to obtain atrial
myocytes from other large mammalian species, with the exception of
cells from the sinoatrial node [100].
6. Myocyte storage solutions
After isolation, freshly dissociated and washed atrial myocytes are
usually transferred to a “storage solution” in which they remain until
usage. For this purpose modiﬁed versions of the Ca2+-free solution or
physiological salinesmaybeused.We and others storedmyocytes in so-
lutions containing EGTA in high concentrations (10 mmol/L) to avoid
reintroduction of Ca2+ into myocytes and prevent the Ca2+ paradox
[24–29,101]. The EGTA was washed out before experimentation
began. However, the authors found that even brief EGTA exposure im-
pairs Ca2+ transient measurements even after a long (N30 min) wash-
ing period with EGTA-free Ca2+-containing (2 mmol/L) bath solution
[31–33].As an alternative to using EGTA, storage solutions may instead con-
tain small amounts of Ca2+ at concentrations somewhat lower than
the physiological range. This provides a gradual reintroduction of
Ca2+ before experimentation begins. BDM may be added to uncouple
excitation–contraction coupling and thereby protect the myocytes
from the Ca2+ paradox.
Isenberg et al. incubated rat and guinea pig ventricular myocytes for
at least one hour in medium containing high K+ but reduced Na+ con-
centrations in order to normalise intracellular Na+/K+ ratios [102,103]
before reintroducing Ca2+. Isenberg et al. designated this solution
“KB-medium” from the abbreviation of the German word Kraftbrühe
for “power soup”. In addition, KB-medium usually contains supplemen-
tal ATP to help maintain a normal Na+/K+ ratio via the sarcolemmal
Na+/K+ pump, as well as maintaining physiological Ca2+ levels via sar-
colemmal and sarcoplasmic reticulum Ca2+ pumps. Substrates for the
glycolytic (glucose) and oxidative (pyruvate) pathways, as well as for
oxidative phosphorylation (succinate, β-OH-butyrate) are added,
to provide energy for Ca2+-activated mitochondrial metabolism.
KB-solution is used to store human [37,104] and large mammalian
[105,106] atrial myocytes.
7. Evaluation of myocytes quantity and quality
When establishing an isolation procedure and also when testing a
new enzyme batch (see above) it is important to evaluate the quantity
and quality of the myocytes that have been isolated. Cell yield can be
quantiﬁed crudely by counting the healthy myocytes in a 10 μl sample.
A microscopic slide with an engraved grid or a Neubauer chamber may
be of help.
Although yield is a good indicator of a successful isolation, other
measures of cell quality can be used. The simplest marker of a high-
quality myocyte is a square-edged rod-shaped appearance with clear
striations. Myocyte health can be further assessed by the cells' ability
to exclude a dye such as trypan blue. It is important to note that this
method is not completely reliable since myocytes, which have taken
up the dye, can still recover from the stresses of isolation and survive
well in culture [9,107]. Finally it is important to evaluate the isolation
procedure based on the experimental parameters, which are studied
in the myocytes and based on the speciﬁc needs of the experimental
question.
It may be assumed that different isolation methods, speciﬁcally
chunk versus perfusion method (see below), can lead to a greater or
lesser loss of cellular constituents such as t-tubules or a speciﬁc ion
channel such as IKr [16]. Using Ca2+ buffers such as EGTA during the iso-
lation procedure can impair cellular Ca2+ transient measurements and
recordings of cell shortening. Accordingly, in our hands, including
EGTA in the storage solution for human atrial myocytes produced artiﬁ-
cial biphasic Ca2+ transients in response to a depolarizing voltage step
(Fig. 1) [108]. The biphasic form could still be observed even after a 10
minute perfusion with EGTA free bath solution. Similarly, BDMmay be
omitted if single cell contractility is of central importance. Response to
ﬁeld stimulation may be an additional indicator of viable atrial
myocytes. However, this parameter might be of limited value in
remodelled cells, because impaired response to electrical activation
may be a component of the remodelling process.
8. Step-by-step procedures
8.1. Isolation of single atrial myocytes from large animals
8.1.1. Use of the perfusion method
Similarly to other laboratories we have found thatwhen tissue is not
limited to small samples or biopsies, as is often the casewith human tis-
sue, a retrograde perfusion system (with solutions ﬂowing retrogradely
down the aorta, as opposed to normal anterograde physiological ﬂow)
employing the use of a Langendorff apparatus is preferable in terms of
Fig. 1. Effect of EGTA during cell isolation on systolic Ca2+ transient in human atrial
cardiomyocytes. A. Representative recordings of L-type Ca2+ current and cytosolic Ca2+
transients in response to a depolarising voltage pulse (whole-cell voltage-clamp
technique). EGTAwas excluded (left panel) during cell isolation or included in the storage
solution (right panel). In both cases, experimentswere started after a 10minute perfusion
with EGTA-free bath solution. B. Normalized traces for both conditions. For detailed
methods see [31,32].
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myocytes isolated using different techniques: when an arterially per-
fused method of atrial myocyte isolation was directly compared with
chunk digestion in dogs, delayed rectiﬁer K+ currents were recordable
from perfusion isolated myocytes but not from those isolated by
chunk digest [16]. While the chunk digest method is used by some
[57,84], theperfusionmethod ismore commonplace. The speciﬁc proto-
col varies between laboratories (Supplemental Table 2).Wewill discuss
methods below, comparing and contrasting those used in different lab-
oratories and species. Details of the speciﬁc protocol we use for isolation
of atrial myocytes from the sheep can be found in the Supplemental
Materials.
8.1.2. Equipment and preparation
The basic equipment required is shown in Fig. 2A. Two physiological
solutions are used. The composition of the solutions used by our group
can be found in Supplemental Table 1, and those of other groups in
Supplemental Table 3. A Ca2+-free [109], low-Ca2+ [61] or cardioplegic
solution [35] is used for initial washing and enzyme perfusion. A
taurine-containing low-Ca2+ solution is used for ﬁnal washing and tis-
sue dissociation. The solutions are stored in reservoirs warmed directly
by a water bath. The warmed solutions pass, via silicone rubber tubing,
to a 3-way tap for easy solution exchange. While our laboratory uses a
peristaltic pump todrive solutions at constantﬂow rate to a Langendorff
coil, other groups use a constant pressure gravity-fed system. Somegroups equilibrate their solutions with oxygen or 5% carbogen [110]
(Supplemental Table 2), but we have not found this necessary in the
isolation of ovine atrial myocytes.
The core of the setup is a Langendorff coil. The outer jacket is
warmed by the water bath, set at 37 °C. Physiological solutions ﬂow
down through the coil until reaching continuity with the base of a cen-
tral column that functions as a bubble trap. The central column exits
downwards to a cannula.
A cannula is attached to the Langendorff coil via another 3 way tap
using silicone rubber tubing. Cannulae are commercially available or
may be fashioned in-house. We use stainless steel rodent gavage
feeders or alternatively nylon peripherally inserted central venous
cannulae that have been cut down. A key feature is the presence of a
terminal lip that facilitates a tight seal with the target vessel by allowing
the cannula to be retracted to the level of the ligature (Fig. 2B).
In order to preserve enzyme containing solution, a recirculation line
driven by the peristaltic pump collects perfusate from the tissue and
returns it to the solution reservoir.
In preparation for cell isolation, the Langendorff coil, cannulae and
all tubing are autoclaved. The equipment is assembled and all lines are
ﬂushed with distilled water. The tubing is then primed with Ca2+-free
and taurine-containing solutions, taking care to remove air bubbles.
The central column of the Langendorff is ﬁlled with Ca2+-free solution
and stoppered. Sutures, syringes and scissors aremade readily available.
8.1.3. Heart extraction and cannulation
An example isolation protocol is shown in theﬂowchart (Fig. 3)with
links to theﬁgure numbered in the text. Twominutes prior to sacriﬁce, a
bolus of 20,000 IU of heparin is administered via a peripheral venous
cannula to reduce the chances of thrombus formationwhich could jeop-
ardise perfusion. Following euthanasia with sodium pentobarbitone
(typically 1 mL/kg of a 20% solution administered intravenously), the
heart is removed via thoracotomy and dissected free at the level of the
ascending aorta (1). At this point, some groups inject cardioplegic solu-
tions into the coronary arteries [34–36]. The heart is then washed in
Ca2+-free solution. Minimising the time between euthanasia and
cannulation preserves cellular viability.
Approaches to cannulation differ between laboratories. In smaller
subjects, direct cannulation of the aorta is used (See Louch et al. for re-
view [9]). In larger species, some groups remove the tissue of interest
and cannulate a vessel within the specimen itself. In our group we
have had most success from cannulating the coronary arteries directly.
The atria are dissected from the ventricles 2 cm below the atrioven-
tricular groove. The aortic root is identiﬁed and the Sinuses of Valsalva
visualised. If left atrial myocytes are required, the ostium of the left
main coronary artery is dissected. Although coronary anatomy varies
considerably, in 60–70% of cases a coronary branch to the left atrial ap-
pendage can be identiﬁed 1–3 cm distal to the ostium of the left
mainstem. A cannula is passed into the vessel and secured using 2–0
silk (2). The cannula is retracted until it rests snugly against the ligature.
If such a branch is not found, the circumﬂex coronary artery which runs
along the atrioventricular groove is cannulated and secured in the same
manner. Similarly, if right atrial myocytes are required, the cannula is
placed within the ostium of the right coronary artery.
Once the cannula has been sited, perfusion is checked using a 50mL
syringe ﬁlledwith Ca2+-free solution. If the circumﬂex or right coronary
arteries have been used, cut vessels are ligated using crocodile clips or
sutures. If perfusion is good, the atrial appendage should blanch. If per-
fusion is poor, the cannula should be manipulated to ensure it is fully
retracted against the ligature, and that the optimal angle between
cannula and vessel has been achieved. Ligated vessels should also be
inspected for leakage.
The 50 mL syringe is disconnected, and the tissue connected to the
Langendorff coil and supported on a collecting vessel. The ﬂow rate is
adjusted to the minimum that achieves good perfusion, marked by
tissue blanching, warmth and slight swelling. Any barriers to good
Fig. 2. A. Isolation setup for the perfusion method of myocytes from atria of large mammals. B. Atrial tissue specimen with nylon cannula perfusing right atrium via right coronary artery.
Note clips on cut edge of ventricle to prevent excessive leakage of solutions. C. (i) Examples of cannulae used for atrial isolation in largemammals. (ii) Left atrial myocyte from sheepwith
patch pipette. LA— left atrium, LMS — left main stem, LV — left ventricle, RA — right atrium, RCA — right coronary artery, RV— right ventricle.
193N. Voigt et al. / Journal of Molecular and Cellular Cardiology 86 (2015) 187–198perfusion such as leaks are rectiﬁed. In our laboratoryweuse a 10minute
wash period without recirculating solutions before applying enzymes
(3). During this time the surface of the tissue is gently rinsed with
Ca2+-free solution to remove any remaining blood.
8.1.4. Enzyme application
Following the wash period, enzyme is added to the Ca2+-free solu-
tion (4). Depending on ﬂow rate, 2–3 min elapses allowing the enzyme
to reach the tissue. After this, the perfusate is collected and recirculated
back to the reservoir to preserve enzyme. Several stages of tissue diges-
tion are observed. The perfusate on the surface of the atrium which is
initially watery becomes viscous and the tissue becomes turgid. As
digestion progresses, translucent regions appear in the appendage and
the tissue becomes ﬂaccid again. The optimum digestion time is inﬂu-
enced by the type and concentration of enzyme use, and also varies
between diseasemodels and individual subjects. In our groupwe adjust
the enzyme concentration so that a 12-minute digest on average yields
viable atrial myocytes from a control sheep. The optimal digestion time
is generally 20% longer in our model of tachypacing-induced heart fail-
ure compared to control due to the atrial collagen deposition seen in
this model. Once digestion has progressed satisfactorily, the perfusing
solution is exchanged for a taurine-containing [109] or KB [106]solution. We employ a 20 minute wash period to remove residual
enzyme (5).
After washing, the atrial appendage is dissected from the remaining
tissue and chopped into 1mm3 chunks (6). The tissue chunks are resus-
pended in ~30 mL of taurine solution and agitated using a Pasteur pi-
pette (7). After three minutes of agitation, 15 mL of the supernatant is
collected via ﬁltration through a nylon mesh into a test tube. 15 mL of
fresh taurine solution is added to the tissue suspension. This is repeated
until 8–10 tubes have been collected. After a settling period, cell pellets
form (8). The supernatant is discarded and the cell pellets reconstituted
with 3 mL of a solution containing a higher concentration of Ca2+. We
use a 50:50 mixture of taurine solution and modiﬁed Tyrode's solution
for this purpose, although other groups employ KB medium [53,106].
8.2. Isolation of single atrial myocytes from humans
8.2.1. Obtaining and transporting tissue
Although in principle whole human hearts can be perfused using a
Langendorff perfusion system [111] we are not aware of any study that
has used the perfusion method to obtain human atrial myocytes. To the
best of our knowledge, all published studies use the so called chunk-
method to obtain human atrial myocytes, which is described below.
Fig. 3. Flowchart for example of perfusion method of isolation of atrial myocytes from
large mammals.
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the tip of the right atrial appendage is usually removed and may be
used for isolation of atrial cardiomyocytes. In patients undergoingmitral
valve replacement, the tip of the left atrial appendage may also be ob-
tained and used for the isolation of left atrial myocytes [29,55]. The sur-
gical technique used to obtain the atrial sample inﬂuences the cell yield.
We found that clamping the right atrial appendage prior to its removal
was associatedwith an 80% reduction in cell yieldwhen comparedwith
resecting the appendage with a purse-string suture only (Fig. 4A). The
mass of atrial appendage removed is also important. We found that tis-
sue samples weighing between 150 mg and 450 mg produced the
highest cell yields, while samples lying outside this range generated
fewer cells (Fig. 4B).
Results obtained from human samples usually have higher variabil-
ity compared to standardised animal models. This may be at least
partially due to patients' characteristics: underlying heart disease,
systemic disease or medication (Supplemental Table 6). We analysed
cell-yields obtained using our standard isolation protocol which includ-
ed EGTA in themyocyte storage solution [25–28,30]. Analysis of covari-
ance (ANCOVA) with stepwise variable selection revealed that chronicAF was associated with decreased cell yield while treatment with
dihydropyridine Ca2+-channel blockers was associated with increased
cell yield. These two factors accounted for ~23% of variability in cell
yield (Supplemental Table 7). Inclusion of other patient characteristics
(Supplemental Table 6) did not improve the model signiﬁcantly. This
suggests that other featureswhichwere not represented in the patients'
recorded characteristics, such as lifestyle and genetics,may also contrib-
ute to cell yield.
We assume that in patients treated with Ca2+-channel blockers, re-
duced cytosolic Ca2+-uptake after reintroduction of Ca2+ during the
isolation procedure may attenuate the detrimental effects of the Ca2+
paradox (see above) thereby increasing cell yield [112]. Similarly, it is
conceivable that impaired cytosolic Ca2+ in patients with cAFmay con-
tribute to reduced cell yield [31,32,37,65]. However, other mediators
such as increased ﬁbrosis and apoptosis may be possible [113].
8.2.2. General procedure for isolation of human atrial myocytes
Although most research laboratories have developed their own iso-
lation methods, there is a common thread which runs through most
published protocols. Within this section we will describe the general
procedure for human atrialmyocyte isolation andwill mention possible
modiﬁcations. As before, a linkedﬂowchart of the procedure is shown in
Fig. 5. Differences between groups in the solution compositions and
enzymes used are shown in Supplemental Tables 4 and 5. A visualised
version of the protocol described here is available online [114].
After excision (1) the tissue sample is transferred immediately into a
sterile transport medium. This is usually based on a cardioplegic solu-
tion in order to reduce energy and oxygen consumption, and prevent
accumulation of toxic metabolites (see above).
During the ﬁrst step of the isolation procedure fat and connective
tissue are removed from the tissue and the sample is chopped into
small chunks of approximately 1 mm3 in size (2). Using a blade instead
of scissors may be advantageous, probably because of the mechanical
damage caused by tugging of the tissue with scissors [115].
Washing the tissue chunks is optional during the isolation process
(3). Although in our experience omitting the washing step does not in-
ﬂuence cell yield, washing the tissue chunks largely removes remaining
blood and results in a clear reduction in erythrocyte count and debris in
the ﬁnal preparation (Fig. 4C). This may be of particular importance in
patch-clamp experiments, where soilings may potentially stick to the
pipette tip and impair seal formation. Washing is usually performed
by transferring the tissue chunks into a washing buffer and stirring
carefully for about 5 min. This step may be repeated 1–2 times.
There is variation between published protocols concerning the
buffers used for these ﬁrst steps. Whereas most groups chop the tissue
in transport solution and use Ca2+-free solution as a washing buffer,
Hatem et al. [59] performed chopping and washing in BDM-containing
transport medium. It is assumed that BDM prevents cutting injury
pointing to a possible advantage of chopping the tissue in BDM-
containing transport medium [116]. However, we and other groups use
Ca2+-free solution for both chopping and washing the tissue [24–33,
117], indicating that there is no clear disadvantage to directly transfer-
ring the tissue to Ca2+-free solution before startingwith the preparation.
For enzymatic digestion, the chopped tissue is placed in a jacketed
reaction beaker containing a magnetic stirring bar (Fig. 4D). The beaker
is warmed to 37 °C and gassed with 100% O2. During the ﬁrst digestive
step, the tissue is stirred for 30–45 min in enzyme solution (4), based
on Ca2+-free solution and containing digestive enzymes such as colla-
genases and proteases (see above). Although the supernatant may
already contain viable cells, a second enzymatic digestion is usually
performed to further increase cell yield.
The tissue is transferred into fresh enzyme solution (5), usually con-
taining collagenases alone. The second digestion is either performed for
a ﬁxed amount of time, established experimentally, or the cell yield of
the supernatant is tested every 2–3 min during the second digestion
step until rod-shaped, striated cardiomyocytes appear. To further
Fig. 4. A. Surgical view of atrial tissue dissected using clamp or purse string suture. Increased cell yield is seen if purse string suture is used. B. Right atrial appendage specimen. Optimal
tissue weight is 0.2–0.4 g. C. Examples of atrial myocytes with and without washing steps. Arrowheads indicate erythrocytes. D. Equipment for isolation of myocytes from human atrial
tissue. RAA — right atrial appendage, RV — right ventricle.
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digestion step using a Pasteur pipette (6). The second digestion step
may be repeated several times with the remaining tissue chunks,
while the supernatants are kept until ﬁnal centrifugation.
To remove large undigested chunks of tissue, the cell containing
supernatant is ﬁltered through a 200 μm nylon mesh (7). Finally, cells
are separated from the supernatants by gentle centrifugation (95 g for
about 10min) and the precipitate is resuspended in 4mL of the storage
solutions described above (8).
9. Conclusions
Cellular dissociation requires a combination of mechanical, chemical
and enzymatic approaches to yield viable cells. The protocols detailed
above may be adapted to the speciﬁc needs of the experimental
question. BDM may be omitted if single cell contractility is of centralimportance. Alternatively, the use of chelating agents such as EGTA
may beminimised if Ca2+ cycling is the primary focus [31–33].Washing
of cellsmay not be required if Ca2+ transients are studied alone butmay
be of beneﬁt if the cells are to be patch-clamped.
Isolation processes have been iteratively improved over the last
three decades and experimental material from human and large mam-
malian subjects is now frequently obtained. The use of isolated
cardiomyocytes provides the unique opportunity to study the cellular
electrophysiological properties that predispose to, precipitate and
perpetuate AF while eliminating interactions between cells. The next
decades will see these techniques used to further our understanding
of atrial physiology in health and disease.
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